The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
Open accessAbstract
Blockade of angiogenesis can retard tumour growth, but may also paradoxically increase metastasis. This paradox may be resolved by vessel normalization, which involves increased pericyte coverage, improved tumour vessel perfusion, reduced vascular permeability, and consequently mitigated hypoxia. Although these processes alter tumour progression, their regulation is poorly understood. Here we show that type 1 T helper (T H 1) cells play a crucial role in vessel normalization. Bioinformatic analyses revealed that gene expression features related to vessel normalization correlate with immunostimulatory pathways, especially T lymphocyte infiltration or activity. To delineate the causal relationship, we used various mouse models with vessel normalization or T lymphocyte deficiencies. Although disruption of vessel normalization reduced T lymphocyte infiltration as expected, reciprocal depletion or inactivation of CD4+ T lymphocytes decreased vessel normalization, indicating a mutually regulatory loop. In addition, activation of CD4+ T lymphocytes by immune checkpoint blockade increased vessel normalization. T H 1 cells that secrete interferon-γ are a major population of cells associated with vessel normalization. Patient-derived xenograft tumours growing in immunodeficient mice exhibited enhanced hypoxia compared to the original tumours in immunocompetent humans, and hypoxia was reduced by adoptive T H 1 transfer. Our findings elucidate an unexpected role of T H 1 cells in vasculature and immune reprogramming. T H 1 cells may be a marker and a determinant of both immune checkpoint blockade and anti-angiogenesis efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We previously demonstrated that vascular normalization could increase immune cells’ infiltration into tumors, and multiple studies have confirmed these findings in several tumor models (15,17-19).”
In the citing paper
“An improved vascular network favors adaptive antitumor immunity by promoting trafficking and re-localization of tumor-infiltrating lymphocytes (TILs), leading to improved outcomes of various immunotherapies, including immune checkpoint blockade (ICB) (15-20).”
In the citing paper
“There is an association of IFNγ-secreting T cells and vessel normalization (18), and IFNγ promotes the enhanced expression of adhesion molecules in endothelial cells (65).”
In the citing paper
“Lack of perfusion, tumoral hypoxia, and T-cell exclusion are considered significant resistance mechanisms (15,17-19).”
In the citing paper
“ICB of cytotoxic T lymphocyte protein 4 (CTLA-4) and PD-1 can normalize blood vessels in multiple models of transplanted breast and other tumours105.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [105]
In the citing paper
“ICB can have vessel-normalizing effects in preclinical models of breast tumours105, although the kinetics of vascular normalization are unknown.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [105]
In the citing paper
“The vascular normalization effect observed in this study was attributed to increased CD4+ type 1 T helper (TH1) cell accumulation and anticancer activity105.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [105]
In the citing paper
“This observation contrasts with the vascular normalization induced by ICB in breast cancer models105 and suggests that the vascular effects are dependent on the tumour location and/or type — a possibility that needs to be further investigated.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [105]
In the citing paper
“although the generalizability of the reciprocal regulation of tumour vessel normalization and immunostimulatory reprogramming is supported by analyses of large transcriptomic databases in human tumours, the experimental studies were limited to breast cancer models105.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [105]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
Robust enumeration of cell subsets from tissue expression profiles
Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 13,224
REVIGO summarizes and visualizes long lists of gene ontology terms
Supek, F., Bošnjak, M., Škunca, N., & Šmuc, T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021800 · Cited by 6,264
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases
Xie, C., Mao, X., Huang, J., Ding, Y., Wu, J., Dong, S., Kong, L., Gao, G., Li, C., & Wei, L. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr483 · Cited by 5,078
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,922
Cited by
Sorted by citations
Items 801–849 of 849
Duan, X., Dai, X., Li, X., Wang, Y., Zhang, K., Chen, W., Chen, Y., Zhao, J., Qiao, Y., Li, X., et al. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158036
Song, G., Hu, J., He, W., Deng, C., Xu, H., Wang, A., Feng, H., Wu, H., Zhu, X., Lu, J., et al. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s587636
Beyond monotherapy: chemotherapy-free strategies in first-line advanced non-small-cell lung cancer
Gorría, T., & Mezquita, L. (2026) · The Lancet Oncology · doi:10.1016/s1470-2045(26)00110-5
Chi, C., Li, L., & Xu, C. (2026) · OncoTargets and Therapy · doi:10.2147/ott.s578933
Yu, Q., Zeng, W., Lin, J., Yu, J., Huang, Y., Zhang, X., Guo, Z., Kong, R., Yu, L., Zhang, X., et al. (2026) · European journal of medical research · doi:10.1186/s40001-026-04267-2
Self-citationPonzo, M. (2020) · theses.fr (ABES) · doi:10.70675/05815fd1z5314z4734z8240zd1a40c5a9bdf
Chen, Y., Zheng, Q., Liu, H., Wu, C., & Feng, Y. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116645
Hu, Y., Zeng, M., Zhang, Y., Zhu, S., Hu, Y., Zhou, S. F., & Xia, F. (2026) · Computer Methods in Biomechanics & Biomedical Engineering · doi:10.1080/10255842.2026.2656292
Xu, J., Zhuang, D., Wang, L. M., Dong, L., Sun, Y., & Xiao, W. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2664297
Jia, K., Ding, Y., Jin, M., Yang, Q., Wang, X., Yan, Y., Xiang, J., Zhang, R., Fang, J., Jiang, J., et al. (2026) · Communications Biology · doi:10.1038/s42003-026-10183-2
Tumor microenvironment evolution in lung cancer: Spatio-temporal dynamics and clinical implications
Dizdarević, S., Timofeev, O., Kazdal, D. N., Pullamsetti, S. S., Sotillo, R., Loges, S., Kobold, S., Stenzinger, A., Stiewe, T., & Savai, R. (2026) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2026.04.003
Fan, X., Liu, X., Mi, S., Yang, Y., Li, C., Zhang, J., & Hu, P. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1767380
Hernández-Camarero, P., Toledo, B., Diaz-Ruano, A. B., Picon‐Ruiz, M., González-Titos, A., Madeddu, R., Marchal, J. A., & Perán, M. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08216-9
Lu, S., Wang, J., Pan, Y., Yang, Y., Huang, J., Li, S., Wang, B., Zhao, S., Ma, N., Zhao, J., et al. (2026) · Integrative Cancer Therapies · doi:10.1177/15347354261450974
Jia, D., Tan, W., Du, J., Zhang, J., Yan, X., Zhang, P., Liang, L., Wen, T., Duan, Y., Su, Y., et al. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118101
Xu, K., Cai, R., Sun, Z., Wang, C., & Bao, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1836760
Boucher, P., Oliveira, M. D. C., Levesque, A., Rutault, A., Savoyaud, P., Bréchot, N., & Germain, S. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70505
Zho, Y.-J., Chiu, T.-Y., & Ho, Y.-J. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127173
Zhu, X., Yu, Y., Si, W., & Xu, J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1841256
Zhang, Q., Lin, L., Wang, W., He, L., Wang, L., Li, W., Zhang, Q., Hu, D., Wu, S. S., Li, W., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-26-0854
Lorestani, P., Robat-Jazi, B., Nejati, N., Jazi, K., Faghihkhorasani, F., Khalili, A., Karimizadeh, Z., Kalantari, A., Mirsharifi, E., Hojjat, S. H., et al. (2026) · Discover Oncology · doi:10.1007/s12672-026-05539-3
Zhang, Y., Jin, Y., Zhang, R., Zhao, J., & Li, B. (2026) · Future Oncology · doi:10.1080/14796694.2026.2701482
Li, S., Neveu, M.-A. C., Kuebler, L., Pezzana, S., Barco-Tejada, A., WILSON, I., González-Menéndez, I., Quintanilla‐Martínez, L., Sonanini, D., Schmid, A. M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.06.743278
Lin, Z., Liu, Q., Li, X., Wang, W., Luo, H., Xia, W., Yuan, Y., Zheng, H., & Luo, W. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103528
Koukourakis, I. M., Verigos, E. K., Verigos, K. E., & Giatromanolaki, A. N. (2026) · Advances in Radiation Oncology · doi:10.1016/j.adro.2026.102164
Dong, M., Zhang, T., Huang, Y., Liu, M., Yuan, Y., Liu, B., Ma, Q., Zhang, H., Huang, C., Shi, C., et al. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04906-0
Mechanisms for Enhancing Radiosensitivity in Esophageal Cancer
Guo, D., Jin, J., Su, X., Yang, W., Guo, B., 焦文鹏, & He, Y. (2026) · Cancers · doi:10.3390/cancers18162610
Microenvironment-defined priority pathways shape ICD-driven abscopal responses
Sun, X., Guo, D., Wang, Z., & Sun, P. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1933591
Nishiyama, Y., Kudo, K., Izawa, M., Goto, S., Ogasawara, K., Kasai, D., Tsuruta, S., Wakasa, Y., Nagase, H., Kijima, H., et al. (2026) · Human Pathology · doi:10.1016/j.humpath.2026.106238
Chen, E., Cao, G., & Song, Z. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189688
Xu, J., Yang, P., Yang, X., Shu, Y., Zhang, L., Zhou, J., Li, L., Ren, Y., Yang, Z., Xiao, Y., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01174
Buttiens, K., Zheng, X., Fan, X., Izci, M., Maksoudian, C., Gilabert, I. P., Chu, T., Goncalves, F. R., Dehairs, J., Swinnen, J., et al. (2026) · Advanced Science · doi:10.1002/advs.77310
Tumor’s own blood supply: Decoding vasculogenic mimicry through hypoxia, EMT, and epigenetics
Wang, Y., Hou, Y., Yu, Q., Lv, S., Li, Y., Zhang, H., & Li, W. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105558
Vascular–immune zonation sets organ-specific metastatic checkpoints
Zheng, Z., Ou, M., Chen, Y., & Gan, D. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1944407
Cancer Immunotherapy: Therapeutic Limitations and Next-Generation Precision Strategies
Ko, D., Park, S., Nam, K.-H., Choi, J., & Lee, K. (2026) · Immune Network · doi:10.4110/in.2026.26.e31
秦锡芬, Wang, Z., & Zhu, H. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1897228
Li, L., He, Y., Peikai, T., Chen, J., Gong, X., & Li, X. (2026) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgag102
He, Z., Wang, Z., He, J., Ren, J., Feng, J., & Zhang, X. (2026) · Advanced Materials · doi:10.1002/adma.75085
Self-citationChen, M., Qin, S., Zhan, Y., & Wang, Q. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1978050
The effects of IFNγ on tissue physiology through structural cells
King, I. L., Jabrì, B., Lund, A. W., & Wang, A. (2026) · Nature reviews. Immunology · doi:10.1038/s41577-026-01357-4
Huang, G.-H., Zhu, M.-L., Yan, Q., Zhou, H., Gai, Q., Zhu, Y.-X., Zhang, S., Liu, Z.-D., Chen, W., Liu, J.-P., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218882
Chambial, P., Sharma, A., Sharma, A., Nile, A. S., & Nile, S. H. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.109025
Turning cold tumors hot: Strategies to enhance antitumor immunity
Steffensen, V. G., Bratina, M., Tsiavou, C., Schmiegelow, K., & Zio, D. D. (2026) · The Journal of Experimental Medicine · doi:10.1084/jem.20260378
Liu, J., Deng, W., Dong, X., Zhao, Y., Jiang, L., Long, L., Teng, Y., Yang, D., Yu, J., Chang, X., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15208121
Chen, S., Wang, H., Gan, Y., Zhao, W., Zhang, H., Chen, X., Zhang, W., Liu, X., Liu, Y., Li, Y., et al. (2026) · The Innovation Oncology · doi:10.59717/j.xinn-oncol.2026.100044
Self-citationHuang, Q., Guo, Y., Yin, S., Gan, L., Liu, Z., Ru, W., Lu, Y., Di, S., Nie, F., Yao, S., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1959437
Metadata
- Authors
- Tian, L., Goldstein, A., Wang, H., Ching Lo, H., Sun Kim, I., Welte, T., Sheng, K., Dobrolecki, L. E., Zhang, X., Putluri, N., Phung, T. L., Mani, S. A., Stossi, F., Sreekumar, A., Mancini, M. A., Decker, W. K., Zong, C., Lewis, M. T., & Zhang, X. H.-F.
- Affiliations
- Baylor College of Medicine (US)
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Zhang, Xiaomei
- Zhang, Xiang H.-F.
- ORCID
- Venue
- Nature
- Published
- 2017-04
- Volume
- 544
- Issue
- 7649
- Pages
- 250-254
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5788037
- OpenAlex
- W2601414401
- Cited by
- 841
- References
- 36
- Citations by year
- 2026: 88 · 2025: 98 · 2024: 98 · 2023: 100 · 2022: 92 · 2021: 129 · 2020: 97 · 2019: 63 · 2018: 51 · 2017: 25
- FWCI
- 26.46
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health (1s10od016167-01)
- National Cancer Institute (R00CA151293, R01CA220297, K99CA151293, R21CA185516, U01CA179674, R01CA183878, P30CA125123)
- National Institute of Allergy and Infectious Diseases (P30AI036211, R01AI127387)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK056338)
- National Center for Research Resources (S10RR024574)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Keywords
- tumor immunosuppression, pericyte coverage, tumor hypoxia, CD4+ T cells, Th1 cells, interferon-gamma, immune checkpoint blockade, anti-angiogenic therapy, T cell infiltration, endothelial cells, tumor vasculature, patient-derived xenografts, cancer immunotherapy
- MeSH terms
- Animals, Capillary Permeability, Female, Humans, Interferon-gamma, Mice, Inbred BALB C, Mice, Inbred C57BL, Neoplasms, Neovascularization, Pathologic, Prognosis, CD4-Positive T-Lymphocytes, Cell Hypoxia, Lymphocytes, Tumor-Infiltrating, Th1 Cells, Neovascularization, Physiologic, Adoptive Transfer, Pericytes, Xenograft Model Antitumor Assays, Endothelial Cells, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
